Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia, Myeloid, Acute 4Solid Tumors 2Polycythemia Vera 2Thrombocythemia, Essential 1Rhabdoid Tumor 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Hematologic Diseases 1Glioblastoma 1Colorectal Neoplasms 1Chromosome 17 deletion 1Central Nervous System Neoplasms 1Breast Neoplasms 1

Interventions

venetoclax 6fludarabine phosphate 5Dexamethasone 4ibrutinib 3Peripheral Blood Stem Cell Transplantation 3Melphalan 3pomalidomide 2fludarabine 2Whole-Body Irradiation 2Tacrolimus 2Mycophenolic Acid 2pirtobrutinib 1pembrolizumab 1obinutuzumab 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carmustine, poliferprosan 20 drug combination 1auricularum 1acalabrutinib 1Sirolimus 1RG7388 1Nivolumab 1Maintenance 1Etoposide 1Cytarabine 1Cyclosporins 1Cyclosporine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Chromosome 17 deletion × RG7388 × Clear all
NCT02633059 2024-09-19

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Mayo Clinic

Phase 1/2 Completed
33 enrolled 26 charts
Plasma cell

Chromosome 17 deletion, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡